Recently, Micreos announced that it has received 32 million euros in funding to further develop its innovative endolysins technology platform
.
The platform will not affect beneficial microorganisms like traditional antibiotics, but only target and kill harmful bacteria
.
The funds received will also help Micreos advance its clinical development projects for the treatment of atopic dermatitis, diabetic foot ulcers and blood infections
.
The microbiome in the human body is vital to body function and plays an important role in maintaining the stability of the immune system.
However, the emergence of antibiotics has broken this balance
.
Most antibiotics are "we do not distinguish between the enemy and the enemy".
They will kill the beneficial and harmful bacteria in our body.
Long-term abuse of antibiotics can easily cause imbalance of the flora in the body, reduce immunity, and develop drug resistance
.
Micreos' strategy is to borrow endolysins produced by nature
.
Endolysin is a compound released by phage to dissolve the cell wall from inside the bacteria
.
It has a strong bactericidal ability and can target drug-resistant Staphylococcus aureus and other drug-resistant bacteria, destroy the cell wall of the bacteria, and cause the death of the bacteria
.
Unlike antibiotics, these enzymes only kill specific strains, and their high specificity allows endolysin to kill only harmful bacteria without harming beneficial good bacteria
.
▲Bacteriophages use endolysin to destroy bacterial cell walls (picture source: reference [2])
Among the two current lead drugs, XZ.
700 targets to kill Staphylococcus aureus, including antibiotic-resistant methicillin-resistant Staphylococcus aureus (MRSA), while retaining the epidermis that is beneficial to the skin and conducive to wound healing Staphylococcus epidermidis
.
SP.
800 can target all strains of Staphylococcus
.
The clinical development plan of XZ.
700 and SP.
800 includes the following indications: atopic dermatitis, diabetic foot ulcer, blood infection, and skin T-cell lymphoma
.
Reference materials:
[1] Micreos secures €32 million for its endolysin-based platform as sustainable alternative to antibiotics.
Retrieved September 30, 2021, from https:// -its-endolysin-based-platform-as-sustainable-alternative-to-antibiotics-301388573.
html
[2] Murray et al.
, (2021).
The Advantages and Challenges of Using Endolysins in a Clinical Setting.
Viruses, https://doi.
org/10.
3390/v13040680
